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Abstract 
BACKGROUND: Pulmonary arterial hypertension (PAH) is a progressive disorder and a newly-discovered disease in 
people with end stage renal disease (ESRD). In patients who are hemodialyzed through arteriovenous fistula (AVF), 
the incidence of pulmonary hypertension (PHT) is highly probable. Regarding the main role of the AVF in the 
pathogenesis of PAH and the fact that AVF is the main method of vascular access in patients undergoing dialysis, 
we decided to investigate pulmonary artery pressure (PAP) in patients under chronic hemodialysis. 
METHODS: This was a cross-sectional study. All patients with chronic hemodialysis were divided into two groups 
according to the status of the fistula. The number of cases examined included 100 patients and data were 
analyzed by SPSS software. 
RESULTS: The most common cause of ESRD was hypertension (HTN) followed by diabetes mellitus (DM), polycystic 
kidney disease (PKD), urologic disorders, DM and HTN, combined blood pressure (BP) and PKD, renal stones, and 
other items ultimately. The average creatinine level was 8.59 mg/dl. Therefore, the mean creatinine level of 
patients, although relative to mode and median, was in any case significantly higher than the mean, which was 
predictable according to the ESRD community studied. The mean phosphate level was 5.66 mg/dl, and the mean 
hemoglobin (Hb) was 11.56 g/dl. The mean parathyroid hormone (PTH) and PAP were 558.68 and 27.33 mmHg, 
respectively, and the mean of ejection fraction (EF) was 50.75%. There was a significant difference between the 
mean PAP in the two groups (P = 0.048), as it was higher in the AVF group. 
CONCLUSION: Results of this study showed that AVF and ESRD both were risk factors for high PAP and PHT. 
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Pulmonary artery hypertension (PAH) is a 
progressive disorder that regardless of its 
cause of the illness can complicate cardiac, 
pulmonary, and systemic diseases and also can 
cause an increase in mortality rate.1 PAH is a 
newly-discovered disease in end stage renal 




disease (ESRD).2 In patients who are 
hemodialyzed with arteriovenous fistula 
(AVF), the incidence of pulmonary artery 
pressure (PAP) is highly probable.3 Recently, 
the prevalence of PAH in patients with ESRD 
is about 40%-50%4 and in Iran, it is estimated to 
be 29%-66%.5-9 The normal systolic blood 
pressure (SBP) of the pulmonary artery is  
30 mmHg.10 PAP is supposed to be the systolic 
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position, which is estimated by Doppler 
echocardiography.11 This increase in pressure 
can be due to cardiac, pulmonary, or systemic 
disorders.4,12 AVF is the gold standard for 
hemodialysis, with a success rate of about 84%, 
which is designed to improve the effectiveness 
of hemodialysis.13 The prevalence of AVF in 
American hemodialysis patients is 60.2%.14 A 
good functional AVF is a device that provides 
a blood flow equivalent to 350-400 ml/min.15 
When chronic kidney disease (CKD) 
progresses to ESRD, renal replacement therapy 
(RRT) is essential for survival, and 
hemodialysis is the most common form of 
treatment.16 Cardiovascular events are the 
cause of most deaths in patients with ESRD.17 
A strong direct relationship between PAP and 
age, duration of dialysis treatment, urea, blood 
creatinine, phosphate, and serum parathyroid 
hormone (PTH) levels, cardiac outflow, and 
AVF current (which is associated with anemia 
and increased fluid burden) and an inverse 
relationship between PAP and serum 
bicarbonate and ejection fraction (EF) have 
been reported in patients undergoing 
hemodialysis.4 The size and location of AVF 
are also involved in the PAP enhancement 
mechanism.18 PAH improves after renal 
transplantation, as well as after short AVF 
compression, which indicates the 
pathogenicity of ESRD and AVF in PAH.19 In 
hemodialysis patients with PAH, there is a 
significant increase in cardiac output 
compared with patients without PAP.4 Right 
ventricular SBP (RVSBP) more than 50 mmHg 
is related with a significant reduction in 
survival after transplantation20 and the 
duration of hemodialysis has a strong 
correlation with RVSBP increase.21 In fact, 
ESRD increases the risk of death and 
cardiovascular disease (CVD) and increases 
the need for special health care.22 In clinical 
experience, blood shunt from right to left and 
increased pulmonary blood flow (PBF) are 
common side effects of PAH.23 PAH can have 
adverse effects on the quality of life of patients, 
which is usually very overwhelming.24 Kidney 
transplantation significantly reduces the PAP 
level and makes it close to the normal range.4 
In this study, we try to compare the PAP in 
patients on dialysis with and without AVF in 
Tohid Hospital, Sanandaj, Iran, during 2016. 
Materials and Methods 
This cross-sectional study was conducted on 
patients with ESRD undergoing hemodialysis 
in Tohid Hospital in Sanandaj City during 
2016. The criteria for entering the study were 
all people over the age of 18 who have been 
undergoing hemodialysis for at least 6 months, 
and the exclusion criteria were the 
hemodialysis patients under the age of  
18 years, hemodialysis patients who had 
undergone less than 6 months of their dialysis, 
those with uncontrolled BP (mean BP more 
than 160/100 mmHg before study entry), 
pregnancy, and recent malignancy. All 
patients with chronic hemodialysis were 
studied in the dialysis ward of Tohid Hospital 
in Sanandaj, which were 100 people. Patients 
were classified into two groups according to 
the status of the fistula. Exposure group (I) was 
a group of people who used AVF for dialysis, 
and a non-exposed group (II) was a group of 
people who used non-AVF method for dialysis 
(a permanent, temporary, or graft catheter). 
The case group was divided into three 
subgroups based on the duration of dialysis: 
A: Less than 12 months since the start of 
their dialysis 
B: Between 12-24 months since the start of 
their dialysis 
C: Over 24 months since the start of their 
dialysis  
For both groups, a questionnaire was 
administered including age, sex, cause of 
ESRD, history of smoking, duration of dialysis, 
the presence or absence of AVF, the site of 
AVF (brachialis or radialis), urea, creatinine, 
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as well as the result of echocardiography, all of 
which were available in patients' files and 
were extracted from the patients’ files and 
examination by the student, that the 
questionnaire was completed based on it 
(access to patient file information was taken 
from them). Echocardiography was performed 
by a cardiologist after a dialysis session to 
determine PAP for all patients. Basic 
characteristics and echocardiography variables 
(EF, PAP) were compared in both groups. Data 
were entered into SPSS software (version 24, 
IBM Corporation, Armonk, NY, USA) and 
analyzed by a statistical consultant for 
statistical analysis. Descriptive goals were 
quantitatively calculated with a few statements 
such as mean, median, faces, and tables 
showing graphs. For quantitative analytical 
purposes, the default normality was calculated 
by t-test and otherwise calculated with non-
parametric sampling. Qualitative analytical 
objectives were calculated using qualitative 
methods such as logistic regression. 
Results 
Descriptive results: In this study, 100 patients 
were examined, that all of them (100%) were 
valid. Patients with AVF (positive group) 
included 66 patients (66%), and 34 (34%) 
patients did not have the fistula. 60% of 
patients were older than 60 years old and 40% 
of them aged less than 60 years. 54% of the 
patients were men and 46% were women. 9% 
of them had a history of smoking, and 91% had 
no history of smoking. 
 
Table 1. Frequency distribution of causes of end 
stage renal disease (ESRD) in cases under study 





Valid DM 7 (7.0) 7.1 7.1 
HTN 66 (66.0) 67.3 74.5 
DM and HTN 4 (4.0) 4.1 78.6 
PKD 6 (6.0) 6.1 84.7 
HTN and PKD 3 (3.0) 3.1 87.8 
Urologic disorders 6 (6.0) 6.1 93.9 
Renal stone 3 (3.0) 3.1 96.9 
Other 3 (3.0) 3.1 100 
Total 98 (98.0) 100  
Missing System 2 (2.0)   
Total 100 (100)   
DM: Diabetes mellitus; HTN: Hypertension; PKD: Polycystic 
kidney disease 
  
Table 1 lists the causes of ESRD in which 
major causes including diabetes mellitus (DM), 
hypertension (HTN), DM and BP, polycystic 
kidney disease (PKD), PKD and HTN, 
urological disorders, and renal stone problems 
as well as other factors are calculated. The 
most common cause of ESRD in the current 
study was HTN with 66% of cases, followed by 
DM, PKD, urologic disorders, DM and HTN, 
combined BP and PKD, renal stones, and other 
items ultimately. 
 










(mg/dl) Hb (mg/dl) PTH (Pg/m) 
PAP 
(Pg/m) EF (%) 
Number Valid 100.00 100.00 100.00 100.00 100.00 98.00 85.00 93.00 
Missing 0 0 0 0 0 2.00 15.00 7.00 
Mean 60.75 78.07 8.59 5.66 11.56 558.68 27.33 50.75 
Median 60.50 69.00 7.50 5.10 11.50 380.00 20.00 52.00 
Mode 60.00 60.00 9.30 5.10 10.50 380.00 15.00 60.00 
SD 13.26 72.12 8.59 4.76 1.68 508.69 14.28 11.04 
Variance 175.98 5202.49 73.88 22.68 2.82 258775.06 204.02 122.03 
Skewness -0.04 7.30 8.15 8.87 0.90 1.82 1.03 -1.38 
SES 0.24 0.24 0.24 0.24 0.24 0.24 0.26 0.25 
Minimum 26.00 23.00 1.80 3.00 8.40 26.00 4.50 10.00 
Maximum 94.00 711.00 88.00 51.00 19.30 2400.00 70.00 65.00 
Percentiles 25 53.25 55.00 5.82 4.20 10.50 210.00 15.00 45.00 
50 60.50 69.00 7.50 5.10 11.50 380.00 20.00 52.00 
75 69.75 80.00 9.30 6.25 12.80 720.00 37.00 60.00 
Hb: Hemoglobin; PTH: Parathyroid hormone; PAP: Pulmonary artery pressure; EF: Ejection fraction; SD: Standard deviation;  
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Table 2 is the most important table for the 
present study. This table explores all the 
variables studied in this study. In the case of age, 
the average age of the subjects was 60.75 ± 13.26 
years. The mean of urea was 78.07 ± 72.12. In the 
case of creatinine, the average creatinine level of 
100 patients tested was 8.59 mg/dl. Therefore, 
the mean creatinine level of patients, although 
relative to mode and median, was in any case 
significantly higher than the mean, which is 
predictable according to the ESRD community 
studied. The average phosphate in the  
100 patients examined was 5.66 mg/dl, and the 
mean Hb in 100 patients was 11.56. The mean 
PTH and PAP in 98 patients examined were 
558.68 and 27.33 mmHg, respectively, and the EF 
mean for 100 patients was 50.75%. 
Analytical results: T-test showed that there 
was no significant difference between the mean 
and standard deviation (SD) of quantitative 
variables in the two groups (P > 0.05). There was 
a significant difference between the mean PAP in 
the two groups (P = 0.04), as it was higher in the 
AVF group. Analysis of chi-square test showed 
no significant difference between the duration of 
dialysis period in patients with chronic 
hemodialysis in the two groups (P = 0.04). 
Discussion 
PAH is a progressive disorder that causes 
cardiovascular, pulmonary, or systemic 
diseases and mortality, irrespective of its 
cause.1 This study was conducted on  
100 patients with chronic dialysis in dialysis 
ward of Tohid Hospital in Sanandaj City, in 
2016, in terms of the fistula in one of two 
groups, to determine the average PAH in 
chronic hemodialysis patients with and 
without AVF. In this study, patients with AVF 
(positive group) included 66 patients (66%), 
and 34 (34%) patients did not have the fistula. 
60% of patients were older than 60 years old 
and 40% of them aged less than 60 years. 54% 
of the patients were men and 46% were 
women. 9% of them had a history of smoking, 
and 91% had no history of smoking. 
Recently, the incidence of pulmonary 
hypertension (PHT) in patients with ESRD is 
estimated as 40%-50%.4 The most important 
causes of ESRD in the cases studied are DM, 
HTN, DM and HTN, PKD, HTN and PKD, 
urological problems, and renal stones. The 
most common cause of ESRD in the current 
study was HTN with 66% of cases, followed by 
DM, PKD, urologic problems, DM and HTN, 
HTN and PKD, renal stones, and other items 
ultimately. High BP also increases the risk of 
hemorrhage from the fistula, in addition to the 
high BP side effects, and increases the risk of 
falling. Low BP results in blood thrombosis 
and fistula disruption due to a decrease in 
blood flow. In this study, the mean urea was 
78.07 ± 72.12. In the case of creatinine, the 
average creatinine level of 100 patients tested 
was 8.59 mg/dl. Therefore, the mean 
creatinine level of patients, although relative to 
mode and median, is in any case significantly 
higher than the mean, which is predictable 
according to the ESRD community studied. 
The average phosphate in 100 patients 
examined was 5.66 mg/dl, and the mean Hb in 
100 patients was 11.56 g/dl. The mean PTH 
and PAP in 98 patients examined were 558.68 
and 27.33 mmHg, respectively, and the EF 
mean for 100 patients was 50.75%. Analytical 
results of this study showed that there was no 
significant difference between the mean and 
SD of quantitative variables in the two groups 
(P > 0.05). There was a significant difference 
between the mean PAP in the two groups  
(P = 0.04), as it was higher in the AVF group. 
Analysis of chi-square test showed no 
significant difference between the duration of 
dialysis period in chronic hemodialysis 
patients in the two groups (P = 0.04). 
In a study conducted by Hayati et al., 60 
patients undergoing hemodialysis were 
divided into two groups exactly like the 
present study. In group 1, PAP was higher 
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0% in group 1 and 2, respectively (P < 0.05). 
Also, in comparing PAP prevalence in two 
groups, similar results were obtained in hands. 
It was concluded that higher PAP was 
associated with a higher incidence of PHT  
(P < 0.01). PAP and PHT were significantly 
higher in patients with ESRD undergoing 
continuous hemodialysis with AVF. Therefore, 
AVF was a predictive factor for a higher PAP 
and an increase in the incidence of PHT in 
hemodialysis patients,25 which is somewhat 
similar to the results of our study. In a study 
by Acarturk et al., 32 patients under 
hemodialysis participated in the study, with a 
median time of 32.7 ± 34.1 months to build a 
fistula. Anatomical location was vascular 
dysentery in 24 radial patients and in  
8 brachial patients. There was a correlation 
between mean PAP and cardiac index (r = 0.45, 
P = 0.01), but other variables such as AVF, 
calcium phosphate, PTH activity, fistula 
location, fistula formation time, and PAP were 
not significantly associated. In 14 patients 
(43.7%), PHT was diagnosed. Variables were 
compared between patients with and without 
PHT. Patients with PHT had a significantly 
higher cardiac index (P = 0.03), but there was 
no significant difference between the other 
variables. The mean PAP was found to be 
related to the cardiac index (P = 0.01). 
However, no relation was found between 
mean PAP and AVF, Hb, calcium-phosphorus, 
and PTH levels (P = 0.03).3 In a study by 
Hemnes et al., 91 patients were divided into 
two groups: dialysis patients with PHT  
(40 patients) and without PHT (51 patients). 
The duration of dialysis was 40.5 ± 47.0 
months. DM, HTN, or both were the most 
common causes of ESRD (54%). Of the  
91 patients, 29 patients (32%) had hemodialysis 
by the catheter. 41 patients (45%) had AVF and 
21 patients (23%) had AV grafts. The mean 
dialysis time in the AV graft or AVF group 
was not different from that of the catheter 
dialysis group (P = 0.24). There was no 
difference in age, sex, and race in patients with 
PHT and those without PHT. Patients with 
PHT were more likely to have long-term 
hemodialysis with an average of 52.6 ± 58.2 
months. However, in patients without fistula, 
it was 31.0 ± 33.7 hours (P = 0.02). In patients 
with PHT, the mean serum phosphate level  
(P = 0.04) and calcium (P = 0.50) was lower, 
but the PTH level was higher (P = 0.40) than 
the other group, but it was not very significant. 
However, lower levels of creatinine were 
significant (P = 0.04).26 
Conclusion 
PAH is a progressive disorder and a newly-
discovered disease in people with ESRD. In 
patients who are hemodialyzed through AVF, 
the incidence of PHT is highly probable. 
Regarding the main role of the AVF in the 
pathogenesis of PAH and the fact that AVF is 
the main method of vascular access in dialysis 
patients, we decided to investigate PAP in 
patients with chronic hemodialysis. The 
number of cases examined included  
100 patients. It is the biggest sample in this 
topic until now. The most common cause of 
ESRD was HTN followed by DM, PKD, 
urologic disorders, DM and HTN, combined 
BP and PKD, renal stones, and other items 
ultimately. There was a significant difference 
between the mean PAP in the two groups  
(P = 0.04), as it was higher in the AVF group. 
Finally, our study showed that AVF and ESRD 
both were risk factors for high PAP and PHT. 
Of course, to confirm this hypothesis, we need 
a larger sample size and finally meta-analysis. 
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